Authors
Latest:
Latest Updates on Geographic Atrophy Gene Therapy FOCUS Trial: Nadia K. Waheed, MDThe associate professor from Tufts University School of Medicine discussed the latest updates on the FOCUS trial.
Latest:
Abhishek Gupta, BS, on Addressing Friction Points in the Commercialization of Gene TherapiesThe senior vice president of genetic medicines at Syneos Health discussed the importance of end-to-end thinking and collaboration when bringing gene therapies from development to the market.
Latest:
Mitigating Cytokine Release Syndrome in CAR T for Multiple Myeloma: Krina K. Patel, MD, MScThe associate professor from The University of Texas MD Anderson Cancer Center discussed mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.
Latest:
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MDThe professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Latest:
Nick Boyle, PhD, on Advantages of In Vivo CAR TherapiesThe chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
Latest:
Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple MyelomaOncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Latest:
No Significant Reduction of CRS or ICANS Seen With Sobi's Anakinra in Patient's Receiving Liso-Cel for LBCLThe data, which comes from a phase 2 trial, were presented at the 2025 Tandem Meetings.
Latest:
More Data Supports Approval as Lifileucel Review for Melanoma Pushed BackThe new PDUFA date of lifileucel is set for Februrary 24, 2024.
Latest:
Amy Pooler, PhD, on Improving Gene Delivery to the CNSThe vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.
Latest:
Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACSBradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
Latest:
The Implications of the First Successful Personalized Gene Editing TherapyKiran Musunuru, MD, PhD, and Rebecca Ahrens-Nicklas, MD, PhD, physician-scientists at CHOP, discussed long-term future expectations for personalized gene editing therapy.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
Peter Marks, MD, PhD, on Bringing More Gene Therapies to PatientsThe director of the Center for Biologics Evaluation and Research at the FDA discussed his keynote speech at the 2023 MDA Conference.
Latest:
Cory R. Nicholas, PhD, on Future Plans for Additional Research With Epilepsy Cell Therapy NRTX-1001The cofounder and CEO of Neurona Therapeutics discussed the company’s goals to evaluate the cell therapy in more types of epilepsy and potentially even in Alzheimer disease.
Latest:
Françoise Bernaudin, MD, on alloSCT Superiority Over SOC for Sickle Cell AnemiaThe head of the Referral Center for Sickle Cell Disease and Clinical Research Department at Hôpital Intercommunal de Créteil of the Université Paris Cité discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.
Latest:
Massimo Trucco, MD, on the Potential of Islet Cell TransplantThe director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.
Latest:
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past MelanomaThe professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.
Latest:
Encapsulated Cell Therapy for Retinal DiseasesJohn Pollack, MD, discusses gene therapy advancements for retinal diseases.
Latest:
Shebli Atrash, MD, on BCMA-Directed Therapy Options for Multiple MyelomaShebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.
Latest:
Evaluating Epigenetic Gene Therapy for the Treatment of FSHDAlexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio, discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Latest:
Future Research in Gene and Cell Therapy ConditioningKevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Latest:
Advantages of Concurrently Investigating Gene Therapies in Dogs and HumansDan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
Latest:
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion ChemotherapyThe vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Latest:
Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple MyelomaThe study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
Latest:
Axi-Cel vs Tisa-Cel in R/R Diffuse Large B-Cell Lymphoma : Guenther Koehne, MD, PhDThe deputy director and chief of stem cell transplantation at Miami Cancer Institute discussed the study of axicabtagene ciloleucel vs tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.
Latest:
Jonathan Yen, PhD, on Continuing Research With Prime Editing for Sickle Cell DiseaseThe director of therapeutic genome engineering, St. Jude Children’s Research Hospital discussed challenges with performing prime editing in cells.
Latest:
Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MDThe associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.
Latest:
Bringing Gene Therapies to Market With the Help of MEAsWith a new paradigm of treating previously incurable diseases comes a new pay paradigm for million-dollar therapies.
Latest:
Developing a Safer Allogeneic Cell Therapy for Ovarian CancerMichael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.
